Falgueyret J P, Oballa R M, Okamoto O, Wesolowski G, Aubin Y, Rydzewski R M, Prasit P, Riendeau D, Rodan S B, Percival M D
Department of Biochemistry and Molecular Biology, Merck Frosst Centre for Therapeutic Research, 16711 TransCanada Highway, Kirkland, Quebec H9H 3L1, Canada.
J Med Chem. 2001 Jan 4;44(1):94-104. doi: 10.1021/jm0003440.
Compounds containing a 1-cyanopyrrolidinyl ring were identified as potent and reversible inhibitors of cathepsins K and L. The original lead compound 1 inhibits cathepsins K and L with IC(50) values of 0. 37 and 0.45 M, respectively. Modification of compound 1 by replacement of the quinoline moiety led to the synthesis of N-(1-cyano-3-pyrrolidinyl)benzenesulfonamide (2). Compound 2 was found to be a potent inhibitor of cathepsins K and L with a K(i) value of 50 nM for cathepsin K. Replacement of the 1-cyanopyrrolidine of compound 2 by a 1-cyanoazetidine increased the potency of the inhibitor by 10-fold. This increase in potency is probably due to an enhanced chemical reactivity of the compound toward the thiolate of the active site of the enzyme. This is demonstrated when the assay is performed in the presence of glutathione at pH 7.0 which favors the formation of a GSH thiolate anion. Under these assay conditions, there is a loss of potency in the 1-cyanoazetidine series due to the formation of an inactive complex between the GSH thiolate and the 1-cyanoazetidine inhibitors. 1-Cyanopyrrolidinyl inhibitors exhibited time-dependent inhibition which allowed us to determine the association and dissociation rate constants with human cathepsin K. The kinetic data obtained showed that the increase of potency observed between different 1-cyanopyrrolidinyl inhibitors is due to an increase of k(on) values and that the association of the compound with the enzyme fits an apparent one-step mechanism. (13)C NMR experiments performed with the enzyme papain showed that compound 2 forms a covalent isothiourea ester adduct with the enzyme. As predicted by the kinetic analysis, the addition of the irreversible inhibitor E64 to the enzyme-cyanopyrrolidinyl complex totally abolished the signal of the isothiourea bond as observed by (13)C NMR, thereby demonstrating that the formation of the covalent bond with the active site cysteine residue is reversible. Finally, compound 2 inhibits bone resorption in an in vitro assay involving rabbit osteoclasts and bovine bone with an IC(50) value of 0.7 M. 1-Cyanopyrrolidine represents a new class of nonpeptidic compounds that inhibit cathepsin K and L activity and proteolysis of bone collagen.
含有1-氰基吡咯烷基环的化合物被鉴定为组织蛋白酶K和L的有效且可逆的抑制剂。最初的先导化合物1对组织蛋白酶K和L的抑制作用的IC(50)值分别为0.37和0.45 μM。通过取代喹啉部分对化合物1进行修饰,导致合成了N-(1-氰基-3-吡咯烷基)苯磺酰胺(2)。发现化合物2是组织蛋白酶K和L的有效抑制剂,对组织蛋白酶K的K(i)值为50 nM。用1-氰基氮杂环丁烷取代化合物2的1-氰基吡咯烷,使抑制剂的效力提高了10倍。效力的这种增加可能是由于该化合物对酶活性位点硫醇盐的化学反应性增强。当在pH 7.0的谷胱甘肽存在下进行测定时证明了这一点,这有利于形成谷胱甘肽硫醇盐阴离子。在这些测定条件下,由于谷胱甘肽硫醇盐与1-氰基氮杂环丁烷抑制剂之间形成无活性复合物,1-氰基氮杂环丁烷系列的效力丧失。1-氰基吡咯烷基抑制剂表现出时间依赖性抑制作用,这使我们能够确定与人组织蛋白酶K的缔合和解离速率常数。获得的动力学数据表明,在不同的1-氰基吡咯烷基抑制剂之间观察到的效力增加是由于k(on)值的增加,并且该化合物与酶的缔合符合明显的一步机制。用木瓜蛋白酶进行的(13)C NMR实验表明,化合物2与该酶形成了共价异硫脲酯加合物。如动力学分析所预测的,向酶-氰基吡咯烷基复合物中加入不可逆抑制剂E64,如通过(13)C NMR观察到的,完全消除了异硫脲键的信号,从而证明与活性位点半胱氨酸残基形成共价键是可逆的。最后,在涉及兔破骨细胞和牛骨的体外试验中,化合物2抑制骨吸收,IC(50)值为0.7 μM。1-氰基吡咯烷代表一类新型的非肽化合物,可抑制组织蛋白酶K和L的活性以及骨胶原的蛋白水解。